Immune related adverse events as a biomarker in non-melanoma patients treated with programmed death 1 inhibitors (PD-1Is).

3069Background: The PD-1Is pembrolizumab (P) and nivolumab (N) have demonstrated clinical activity in multiple tumor types. They can lead to unique immune related adverse events (irAEs). Studies ha...